All In Biotech

Drug Trial Radar · NCT07581197

Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes

A Phase 1/2 Dose Escalation Study to Evaluate the Safety and Efficacy of SR-02 Pancreatic Endocrine Cell Clusters Implanted in the Omentum of Adults With Type 1 Diabetes (SUGR)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion Nov 2029

Sponsor

Lead sponsor
SeraxisIndustry
Sponsor type
Industry
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to prevent rejection will be required in this first in human study.

Conditions

  • Diabete Mellitus
  • Diabete Type 1

Interventions

  • Allogeneic pancreatic endocrine cell clustersBiological

    Allogeneic pancreatic endocrine cell clusters

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the safety and tolerability of SR-02 when implanted in subjects with T1D and Level 3 hypoglycemia as assessed by CIT-TCAE v5.0.Time frame: Day 35 to Day 365
  2. Change in C-peptide secretion from baseline.Time frame: Enrollment to Day 365

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.